Ziegler Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ziegler Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50,946	Closed	-$346K	–	421
2022 Q1	$346K	Hold	50,946	–	–	0.01%	346
2021 Q4	$425K	Sell	50,946 -17,834	-26%	-$147K	0.02%	378
2021 Q3	$511K	Sell	68,780 -2,317	-3%	-$14.4K	0.02%	382
2021 Q2	$483K	Buy	+71,097	New	+$591K	0.02%	394
2021 Q1	–	Sell	-50,220	Closed	-$352K	–	445
2020 Q4	$352K	Sell	50,220 -5,842	-10%	-$45.5K	0.01%	396
2020 Q3	$457K	Buy	+56,062	New	+$348K	0.02%	381

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Ziegler Capital Management's JNCE Position: Q2 2022 in Review

Ziegler Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 50,946 shares — an estimated $346K sold.

Ziegler Capital Management first reported a position in JNCE in Q3 2020 and held it in 6 quarters. The position peaked at $511K in Q3 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Ziegler Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Ziegler Capital Management sold 50,946 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $346K.
Ziegler Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Ziegler Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $511K in Q3 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ziegler Capital Management's 13F filing for Q2 2022, filed 21 Jul 2022.